Hypogonadism in Men. CME Away India & Sri Lanka March 23 - April 7, 2018
|
|
- Arline Parks
- 5 years ago
- Views:
Transcription
1 Hypogonadism in Men CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi
2 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or mechanical, including photocopying, recording, or information storage and retrieval systems without prior written permission of Sea Courses Inc. except where permitted by law. Sea Courses is not responsible for any speaker or participant s statements, materials, acts or omissions.
3 Barriers To Change
4 Disclosure of Commercial Support This program has not received financial support, or in-kind support, from any Pharmaceutical Company. Potential for conflict(s) of interest: None to declare
5 Faculty/Presenter Disclosure Faculty: Richard Bebb Relationships with commercial interests: None to report
6 Faculty/Presenter Disclosure Nothing to Disclose
7 Learning Objectives: Recognition of hypogonadism in men Treatment of hypogonadism in men Safety Issues CVD, Prostate & Thrombotic Risk
8 Hypothalamus GnRH Pituitary Testosterone LH FSH Testis Adapted from Bagatell CJ, Bremner WJ. N Engl J Med. 1996;334: Testosterone Sperm
9 Hypogonadism sub-types: Primary (testicular) Low T, high LH and FSH Secondary (pituitary/hypothalamic) Low T, low or inappropriately normal LH and FSH Mixed primary and secondary (eg age related hypogonadism)
10 Clinical Approach to Hypogonadism Primary: Secondary: Irreversible Replace T if indicated Fertility is not possible a) Structural: Irreversible Replace T if indicated Fertility is possible b) Functional: May be reversible Replace T if indicated Fertility is possible
11 Secondary Hypogonadism Structural Pituitary tumor Pituitary radiation Traumatic brain injury Hemochromatosis (most) Functional Hyperprolactinemia Obesity Sleep Apnea (some) Opioids Post exogenous T exposure Medication exposure (eg prednisone)
12 Hypogonadism: Signs & symptoms Loss of strength, energy, motivation 1,2 Decrease in lean body mass, muscle volume; increased visceral fat 1,2 Fatigue, lethargy, sleep disturbance 1,2 Decrease in body hair; skin alterations 2 Diminished libido, erectile dysfunction 1,2 Mood and cognitive changes 1,2 1. Practice Committee (ASRM).Fertil Steril 2004;81: Nieschlag E, Swerdloff R, Behre HM et al. The Aging Male 2005;8(2):56-8.
13 Clinical Manifestations 1,2 Decreased libido Decreased vitality Fatigue Mood changes Insomnia Anemia Delayed ejaculation Flushes Erectile dysfunction Decreased muscle mass Increased visceral body fat Testicular atrophy Weakness Osteopenia/osteoporosis Loss of facial, axillary and pubic hair Degree of Deficiency Manifestations may present alone or in combination 1. Liu PY, et al. J Clin Endocrinol Metab. 2004; 89: Zitzmann M, et al. J Clin Endocrinol Metab. 2006;91:
14 ACTION SITES OF TESTOSTERONE Brain: hippocampus, frontal lobes Skin: hair growth, sebaceous glands Liver: protein synthesis Adipose tissue: control of leptin Muscles: volume and strength Marrow: hematopoietic cells Joints: synovial sheaths Bone: protein matrix Kidney: erythropoietin Prostate: development and function
15 Hypogonadism: Prevalence HIM Study Prevalence rate and odds ratio for hypogonadism by risk factors Mulligan T et al. Int J Clin Pract 2006;60:
16 Testosterone: When to measure Presence of symptoms 1,2 Unexplained anemia 1 Osteopenia/Osteoporosis 1 Type 2 Diabetes 3 1. Practice Committee (ASRM).Fertil Steril 2004;81: Nieschlag E, Swerdloff R, Behre HM et al. The Aging Male 2005;8(2): Bhasin S, et al. J Clin Endocrinol Metab. 2006;91:
17 Diurnal Cycle of Testosterone Bremner et al. J Clin Endocrinol Metab 1983;56:
18 Testosterone: Measuring & testing Bioavailable testosterone Total Testosterone
19 Initial Diagnosis 1 Tests to be included: Repeat T FSH CBC SHBG LH Ferritin Prolactin TSH PSA/DRE 1. Morales A, et al. CUAJ. 2010;4(4);
20 Diagnostic Triad for Hypogonadism Signs & Symptoms + Biochemical Confirmation Evidence + Response to Therapy Modified from Nieschlag E, Swerdloff R, Behre HM et al. The Aging Male 2005;8(2):56-8.
21 It is not just in the numbers.. Endocrine Society Guidelines: low levels (alone) do not establish a diagnosis of hypogonadism Canadian Guidelines: Androgen deficiency is a Clinical Diagnosis supplemented by Laboratory Testing (Dr. Dan Holmes) A Syndromic Diagnosis compared to: - Outcome Defined Normal Range: BP, Cholesterol, HgA1c - Normal Population Distribution: Calcium, CBC, folate
22 Benefits of Testosterone Replacement: (in Hypogonadal men) Sexual function Mood Energy Lean body mass Bone mineral density Fat mass Wang C et al. J Clin Endocrinol Metab 2004;89:
23 Symptom Improvement Timeline of Symptom Improvement 1 Enhanced libido Improved emotional well-being Increased energy Reduced ED Increased strength Enhanced BMD Improved cognition Enhanced cardiovascular health Decreased body fat Improvement in some components of MetS Duration of Treatment (months) 1. Morales A, et al. CUAJ. 2010;4:
24 Healthy Man Study Serum Testosterone (nmol/l) Testosterone Serum T did not vary with age n=325 men, 2900 serum specimens Age (years) Sartorius G et al Clin Endocrinol 2012 ;77:755
25 European Male Aging Study (EMAS) Relationship between Age and Testosterone in 3220 Men Wu FCW et al. J Clin Endocrin Metab 93(7): (2008)
26 European Male Aging Study (EMAS) Relationship between Age and Testosterone in 3220 Men BMI <25 BMI BMI Wu FCW et al. J Clin Endocrin Metab 93(7): (2008)
27 European Male Aging Study (EMAS) Relationship between Age and Testosterone in 3220 Men BMI <25 BMI BMI At BMI ~35, ½ of men in 2 0 hypogonadal range Wu FCW et al. J Clin Endocrin Metab 93(7): (2008)
28 European Male Aging Study (EMAS) Relationship between Age and Testosterone in 3220 Men Co-morbidities and fall in serum T at any age Wu FCW et al. J Clin Endocrin Metab 93(7): (2008)
29 Effect of weight loss on testosterone levels in Men with Type 2 Diabetes (n=10 to 58 men, 5 to 50 kg loss). Testosterone and the Metabolic Syndrome Grossmann M JCEM 2011;96:
30
31 T Trial population Men > 65 years Serum total T <275 ng/dl plus 2 nd <300 ng/dl One or more symptoms potentially related to low testosterone
32 T Trials General enrolment criteria plus specific criteria for some trials; Physical Function Trial Sexual Function Trial Vitality Trial Cognitive Function Trial Anemia Trial Cardiovascular Trial Bone Trial Testosterone target range ng/dl
33 Outcomes of T Trial in Aging (co-morbid) Men Sexual Function - Modest & transient benefits in some aspects ED: PDE5 inhibitors are more effective. Cognition and memory - not improved Vitality and fatigue -no benefits Physical function - some benefits in some testing procedures Bone - density improved: not compared to established therapies
34
35 GnRH Testosterone: Three hormones in one LH Testosterone 6 mg/day aromatase (0.2%) Hepatic oxidation & conjugation Renal excretion 5α-reductase (5-10%) Amplification (prostate, skin) DHT Direct pathway (muscle) Estradiol Diversification (brain, bone) Androgen receptor Androgen receptor Y Estrogen receptor Inactivation pathway D Handelsman
36 T and E 2 needed for optimal male health 400 healthy men years: GnRH agonist down-regulation Te (or placebo) gel g daily for 16 weeks +/- anastrozole to block E2 synthesis Androgen deficiency: lean mass, muscle size, and strength Estrogen deficiency: increases in body fat Both contributed to decline in sexual function. Finkelstein JS et al N Engl J Med. 2013;369:1011
37 Implications of Three hormones in one Relative estrogen deprivation using nonaromatizable androgens (SARMs) or aromatase inhibitors can produce osteoporosis so: DO NOT USE!! Native testosterone is the treatment of choice
38 Current Treatment Options Intramuscular - Depo-Testosterone (T cypionate) - Delatestrel (T enanthate) - Nebido (T undecanoate) - Sustanon (30 mg Testosterone propionate mg Testosterone phenylpropionate mg Testosterone isocaproate mg Testosterone decanoate) Oral - Andriol / Testocaps (T undecanoate) Testosterone patch Androderm (Testosterone) Testosterone gels - Androgel (1%, 1.6% Testosterone) - Testim (1% Testosterone) - Axiron (2% Testosterone) Other: T Pellets, T buccal, T nasal
39 Injectable Testosterone Advantages Infrequent administration Lower cost T undecanoate can be clinic administered Disadvantages Fluctuating blood level effects on libido, energy, and mood with short acting esters No diurnal cycle Polycythemia more common The Needle
40 Testosterone Undecanoate (oral) Advantages Oral Invisible Convenient Not hepatotoxic Disadvantages Variable absorption No diurnal cycle 2 to 3 times per day Must be taken with fatty foods Expense
41 Androderm Advantages Consistently Testosterone levels Mimics diurnal cycle Convenient, oncedaily therapy Disadvantages Visible Skin irritation can occur Expense
42 Androgel / Testim / Axiron Advantages Consistently Testosterone levels Mimics diurnal cycle Convenient, oncedaily therapy Disadvantages Potential for partner transfer (? Not Axiron) Expense Aroma (Testim)
43 Other T Methods T Pellets: surgical, extrusion, infection, cost Buccal: Frequent dosing, irritation Nasal: Cost, potential to limit transference
44 Contraindications suspected or confirmed carcinoma of the prostate or breast 1,2 significant polycythemia (hematocrit>50%) 1,2 untreated sleep apnea 1,2 severe heart failure (eg, class III or IV) 1,2 severe symptoms of lower urinary tract obstruction 1,2 clinical evidence of bladder outflow obstruction 1 undiagnosed prostate nodule or induration 2 unexplained elevation in PSA 2 1. Nieschlag E, Swerdloff R, Behre HM et al. The Aging Male 2005;8(2): Bhasin S, Cunningham GR, Hayes FJ et al. J Clin Endocrinol Metab 2006;
45
46 Treatment Safety
47 Vigen R et al. J Am Med Assoc 310(17): (2013)
48 Retrospective, non-randomized, observational study of 8,709 men, 61 to 64 yrs, who had undergone coronary angiography with a low serum total testosterone. Study Group Testosterone Rx Control Group Number of Subjects Deaths MI CVA Total Events/ group Event Rate before stats Event Rate after stats % 25.7% % 19.9%
49 INCORRECT EXCLUSION SKEWED RESULTS Once MI or stroke occurred, men were no longer in the riskset Irrelevant whether or not they received T If included, this increases number of events in no-t group by 71% ( )
50 It gets worse. 9% of Vigen cohort found to be female!! Take Home Point: The Vigen Study is Rubbish
51 Shores M., et al. Arch Intern Med. 2006;166: Hazard Ratio: % CI: P < Low T associated with increased mortality Testosterone level Mortality 95% CI Normal 20.1% % Equivocal 24.6% % Low 34.9% % After adjusting for age, medical morbidity and other clinical covariates, low testosterone levels continued to be associated with increased mortality.
52 Survival of treated vs untreated T-deficient men N=1031 Men>40y T<250 ng/dl Mortality: 20.7% untreated 10.3% T treated P< Shores et al, JCEM 2012
53 T Deficiency in DM Associated With Increased Mortality, Reversed with T Therapy 581 men T2DM F/u 5.8y Low T defined <300ng/dl (10.4 nmol/l Men with low T untreated HR 2.3 (CI95% ; p=0.004) T therapy- Reduced from 19.2% to 8.4% Muraleedharan V et al. Eur J Endocrin 2013
54 Endocrine Society Guidelines There have been no RCTs that were large enough or long enough to determine the effects of T replacement therapy on major adverse cardiovascular events (MACE). In addition, there is no conclusive evidence that T supplementation is associated with increased cardiovascular risk in hypogonadal men.
55 Prostate Safety: Historical review Does exogenous testosterone cause prostate cancer to grow? based on result from one patient Current evidence no increase in cancer rates in clinical trials of TRT in normal men or men at increased risk no relationship of cancer risk with serum testosterone levels no reduced risk of cancer in men with low testosterone Morgentaler, A. Euro Urol 2006;50:
56 ng/dl ng/g Median serum [DHT] but no Δ in prostate [DHT] with Im T rx in older hypogonadal * Baseline prostate [DHT] Treatment prostate [DHT] JAMA. 2006;296:
57 Prostate Conclusions: No increase in prostate cancer rates in clinical trials of TRT in normal men or men at increased risk for PCa 1 Low serum free testosterone may be a marker of more aggressive prostate cancer 2 TRT results in: Modest in gland size (to eugonadal level) 3 No deterioration in urine flow, obstructive symptoms or other prostate symptoms 3 1 Morgentaler, A. Euro Urol 2006;50: Hoffman et al. J Urol 2000;163: Tremblay RR, Morales A. Aging Male 1998;1:
58 Testosterone and risk of venous thromboembolism VE: case-control study across 370 general practices in UK 19, 215 confirmed VEs (DVT, PE) 909, 530 age matched controls 10.0 additional VEs above the base rate of 15.8 per person years. Starting testosterone Rx is associated with increased risk of VE peaking in 1 st six months Many of these patient may have a hereditary thrombophilia Martinez et al BMJ :i5968
59 Monitoring Men on Testosterone Therapy For first year, patients should be monitored at 3, 6 and 12 months Assessment should include: Evaluate response to therapy Conduct DRE Measure: serum testosterone level selectively PSA Hematocrit (target <52%) liver function selectively HDL and cholesterol/hdl ratio Patients who remain stable may subsequently be followed up annually
60
Hypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated.
Male Hypogonadism -- Definition - Low T, Low Testosterone Hypogonadism -...a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone due to pathology
More informationEvaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients
Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Jeff Unger, MD Director Chino Medical Group Diabetes and Headache Intervention Center Chino, California January 16, 2008
More informationManaging Testosterone Deficiency: A Practical Guide. John Grantmyre MD Professor of Urology Dalhousie University
Managing Testosterone Deficiency: A Practical Guide John Grantmyre MD Professor of Urology Dalhousie University 1 2 Case Study #1 A 59-Year-Old Man with Erectile Dysfunction 3 Case History Robert is a
More information6/14/2010. GnRH=Gonadotropin-Releasing Hormone.
Male Androgen Replacement Mitchell Sorsby, MD June 19, 2010. QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression
More informationHow to treat: TRT modalities and formulations
How to treat: TRT modalities and formulations Paul PIETTE, PharmD Senior Research Fellow Clinique Antoine Depage - Belgium ppiette@besins-healthcare.com Bruges 2014, May 15 th Testosterone-replacement
More informationTestosterone Treatment: Myths Vs Reality. Fadi Al-Khayer, M.D, F.A.C.E
Testosterone Treatment: Myths Vs Reality Fadi Al-Khayer, M.D, F.A.C.E The Biological Functions of Testosterone in Men Testosterone is essential to the musculoskeletal and metabolic systems throughout a
More informationGUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde
GUIDELINES ON Male Hypogonadism G.R. Dohle, S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely
More informationTestosterone Therapy in Men An update
Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None
More informationTestosterone Therapy in Men with Hypogonadism
Testosterone Therapy in Men with Hypogonadism (Endocrine Society 2018 Guideline) Ngwe Yin, MD Assistant Clinical Professor of Medicine, UCSF Fresno Medical Education Program Disclosures None Objective
More informationA dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male
Androgen Replacement Therapy in the Aging Male Thomas J. Walsh, MD, MS Department of Urology University of California, San Francisco Objectives 1. List 3 effects of androgens on normal male physiology.
More informationLate onset Hypogonadism. Dr KhooSay Chuan Department of Urology Penang General Hospital
Late onset Hypogonadism Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset hypogonadism(loh) Definition LOH age associated testoteronedeficiency syndrome (TDS) Male menopause, andropause,
More informationPoint-Counterpoint: Late Onset Hypogonadism (LOH)
Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx
More informationMen Getting Older Will Testosterone Keep Him Young?
Men Getting Older Will Testosterone Keep Him Young? Alvin M. Matsumoto, M.D. Associate Director, GRECC V.A. Puget Sound Health Care System Professor, Department of Medicine Division of Gerontology and
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
TESTOSTERONE REPLACEMENT THERAPY: ANDRODERM transdermal patch ANDROGEL pump transdermal gel and transdermal gel AXIRON transdermal solution FORTESTA transdermal gel NATESTO nasal gel STRIANT buccal mucoadhesive
More informationRecognizing and Managing Testosterone Deficiency
Recognizing and Managing Testosterone Deficiency J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships
More informationProf Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA
Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA Prevailing context Increase number of men who are potential candidates for Testosterone Replacement Therapy
More informationUpdate on Androgen Deficiency. Acknowledgments. Curatio PowerPoint TemplateControversies in Male Hypogonadism Bradley D.
The General Practice Education Day Healthed / Generation Next August 22 nd Sydney Update on Androgen Deficiency Robert I. McLachlan, FRACP, PhD Director, Andrology Australia Principal Research Fellow,
More informationHow to Recognize Adrenal Disease
How to Recognize Adrenal Disease CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi
More informationDiagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ)
Diagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ) Alvaro Morales CM MD, Richard A. Bebb MD, Priya Manjoo MD MSc, Peter Assimakopoulos MD, John
More informationANDROGEN DEFICIENCY Update on Evaluation and Management
ANDROGEN DEFICIENCY Update on Evaluation and Management Kristen Gill Hairston, MD, MPH Associate Professor of Internal Medicine Section of Endocrinology and Metabolism Wake Forest University School of
More informationANDROGEN DEFICIENCY/MALE HYPOGONADISM
Medical Information to Support the Decisions of TUE Committees 1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of
More informationHYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY)
HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY) DEFECT OF THE REPRODUCTIVE SYSTEM THAT RESULTS IN LACK OF FUNCTION OF THE GONADS (Wikipedia) REDUCTION
More informationANDROGEN DEFICIENCY/MALE HYPOGONADISM
ANDROGEN DEFICIENCY/MALE HYPOGONADISM 1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of testosterone (androgen deficiency)
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
TESTOSTERONE REPLACEMENT THERAPY: ANDRODERM transdermal patch ANDROGEL pump transdermal gel and transdermal gel ANDROID (methyltestosterone) oral capsule ANDROXY (fluoxymesterone) oral tablet AXIRON transdermal
More informationCorporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency
Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency
More informationDisclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None
Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone
More informationAndroderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical
More informationEndocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
More informationAndrogens. Medication Strengths Quantity Limit Comments Androderm (testosterone patch) 1% pump 2 pump bottles per Non-Preferred
Market DC Androgens Override(s) Prior Authorization Quantity Limit Approval Duration Varies upon diagnosis Medication Strengths Quantity Limit Comments Androderm (testosterone patch) AndroGel (testosterone
More informationWhat Is the Low T Syndrome? Is Testosterone Supplementation Safe?
What Is the Low T Syndrome? Is Testosterone Supplementation Safe? UCSF Osher Mini Medical School March 7, 2018 Dolores Shoback, MD Staff Physician SF-VAMC Professor of Medicine, UCSF No disclosures or
More informationCurrent Data and Considerations Novel Testosterone Formulations
Current Data and Considerations Novel Testosterone Formulations 1 Hypogonadism: Treatment Safety and Prostate Health 2 Monitoring for Testosterone Therapy DRE 1,2 PSA Parameter Voiding/IPSS 1,2 Hemoglobin
More informationMALE HYPOGONADISM: CHOOSING THE APPROPRIATE THERAPY. Michael S. Irwig, M.D. Director, Center for Andrology Division of Endocrinology & Metabolism
MALE HYPOGONADISM: CHOOSING THE APPROPRIATE THERAPY Michael S. Irwig, M.D. Director, Center for Andrology Division of Endocrinology & Metabolism Disclosures Aromatase inhibitors & clomiphene citrate are
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: December 8, 2017 Testosterone
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: November 30, 2018 Testosterone
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Acquired hypogonadism, prevalence of, 165 167 primary, 165 secondary, 167 Adipose tissue, as an organ, 240 241 Adrenal hyperplasia, congenital,
More informationMale Hypogonadism. Types and causes of hypogonadism. What is male hypogonadism? Symptoms. Testosterone production. Patient Information.
Patient Information English 31 Male Hypogonadism The underlined terms are listed in the glossary. What is male hypogonadism? Male hypogonadism means the testicles do not produce enough of the male sex
More informationGUIDELINES ON MALE HYPOGONADISM
GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by androgen
More informationHormone Replacement Therapy
Hormone Replacement Therapy What Role Should It Play With Our Patients? Noel R. Williams MD, FACOG TESTOSTERONE FOR MEN: SALVATION OR SNAKE OIL? Definition Male hypogonadism means the testicles don't produce
More informationEAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone
More informationTestosterone Injection / Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Testosterone Injection / Implant Page: 1 of 9 Last Review Date: December 5, 2014 Testosterone
More informationOutline. Classic Androgen deficiency. Cardiovascular Risk and Testosterone Fact vs Fiction. Professor Robert I McLachlan AM, FRACP, PhD
Health Ed Brisbane Saturday 27 th October 2018 Cardiovascular Risk and Testosterone Fact vs Fiction Professor Robert I McLachlan AM, FRACP, PhD Hudson Institute of Medical Research, Monash University Department
More informationTestosterone Therapy and the Prostate. Frans M.J. Debruyne Professor of Urology The Netherlands
Testosterone Therapy and the Prostate Frans M.J. Debruyne Professor of Urology The Netherlands TRT- Risks Prostate ( Cancer, BPH )? Cardiac? Lipids? Polycythemia Sleep apnea Gynecomastia Edema Testosterone
More informationDidactic Series. Hypogonadism and HIV. Daniel Lee, MD UCSD Medical Center, Owen Clinic July 28, 2016
Didactic Series Hypogonadism and HIV Daniel Lee, MD UCSD Medical Center, Owen Clinic July 28, 2016 This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department
More informationClinical Policy: Testosterone Pellet (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date:
Clinical Policy: (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date: 07.25.17 Last Review Date: 11.17 Line of Business: Commercial Coding Implications Revision Log See Important Reminder
More informationPeter J. Burrows MD FACS
Testosterone Supplementation, Prostate Cancer Screening and Vitamins Peter J. Burrows MD FACS Clinical Assistant Professor of Urology University of Arizona, College of Medicine Adjunct Assistant Professor
More informationOver the past decade, androgen replacement
J. Andrew Hoover, MD; Jeffrey T. Kirchner, DO, FAAFP Department of Family and Community Medicine, Lancaster General Hospital, Pa jhoover4@lghealth.org The authors reported no potential conflict of interest
More informationAndrogen deficiency. Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital
Androgen deficiency Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital Outline Pathological androgen deficiency - Background, causes, interpretation - Indications for treatment Androgen
More informationUpdate on diagnosis and complications of adult and elderly male hypogonadism
Hypoandrogenism in the elderly: to treat or not to treat? 12 th Italian AME Meeting; 6 th joint Meeting with AAC Bari november 10th Update on diagnosis and complications of adult and elderly male hypogonadism
More informationEAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Limited text update March 2017) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch Introduction Male hypogonadism is a clinical syndrome caused by androgen
More informationLate onset hypogonadism
Late onset hypogonadism Farrukh Javid Male Menopause Clinical AND biochemical syndrome Testosterone levels decline by 0.4-3% per year after the age of 30, as opposed to the more rapid decline that occurs
More informationTestosterone (cypionate, enanthate, and propionate) powder, Fluoxymesterone powder, Methyltestosterone powder
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.37 Subject: Testosterone Powder Page: 1 of 12 Last Review Date: November 30, 2018 Testosterone powder
More informationGA KS KY LA MD NJ NV NY TN TX WA Applicable X X N/A N/A X N/A X X X X X X N/A N/A NA *FHK- Florida Healthy Kids. Androgens
Androgens Override(s) Prior Authorization Quantity Limit Approval Duration Varies upon diagnosis Medication Strengths Quantity Limit Comments Generic Androgel 1% (2.5 g) packet 2 packets per day (testosterone
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone Oral Buccal Nasal Description
More informationPRISM Bruges June Herman Leliefeld Urologist. The Netherlands
PRISM Bruges 25-26 June 2015 Herman Leliefeld Urologist The Netherlands Guidelines EAU 2015: a rich source of Knowledge! Epidemiology/ Aetiology / Pathology Diagnostic evaluation Disease management Follow-Up
More informationISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN
International Society for Sexual Medicine - www.issm.info ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN Version: September 2015 What is testosterone deficiency? Testosterone deficiency
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: November 30, 2018 Testosterone Oral Buccal Nasal
More informationProf. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany
Induction of fertility in hypogonadal men Prof. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany Induction of fertility in hypogonadal men Prof.
More informationTestosterone Replacement. Seacourses Dec 30, 2017 January 6, 2018 Dr. Stacy Elliott
Testosterone Replacement Seacourses Dec 30, 2017 January 6, 2018 Dr. Stacy Elliott Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or
More informationHormone Therapy Overview for the Behavioral Health Provider. Julie Thompson, PA Fenway Health
Hormone Therapy Overview for the Behavioral Health Provider Julie Thompson, PA Fenway Health Continuing Medical Education Disclosure Program Faculty: Julie Thompson, PA Current Position: Physician s Assistant,
More informationTestosterone Replacement Therapy for Hypogonadism: Learning Objectives. What Is the Evidence? Is It Safe? Case Study. Case Study contd.
4 4:4pm Testosterone Therapy: Examining the Evidence SPEAKER Culley Carson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Culley Carson, MD: Consultant
More informationBIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE
Authoriser: Moya O Doherty Page 1 of 7 BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE The purpose of this protocol is to describe common tests used for the investigation
More informationPCa Commentary. Prostate Cancer? Where's the Meat? - A Collection of Studies Supporting the Safety of Its Use. Seattle Prostate Institute CONTENTS
Volume 70 July - August 2011 PCa Commentary SEATTLE PROSTATE INSTITUTE CONTENTS TESTOSTERONE REPLACEMENT in Hypogonadal Men with Treated and Untreated Prostate Cancer? 1 TESTOSTERONE REPLACEMENT in Hypogonadal
More informationTestosterone (cypionate, enanthate, and propionate) powder, Fluoxymesterone powder, Methyltestosterone powder
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.37 Subject: Testosterone Powder Page: 1 of 11 Last Review Date: September 18, 2015 Testosterone powder
More informationBest Practices to Improve Patient Outcomes
Best Practices Pearls Practical Primary Care Strategies for Diagnosing and Managing Hypogonadism in Men Utilize lab testing in appropriate patients who have complaints consistent with the often subtle
More informationAn Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health
An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health KEVIN R. LOUGHLIN MD,MBA Harvard Medical School Boston, MA THE WEAKER SEX-MALES LIFE EXPECTANCY
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: June 24, 2016 Testosterone Oral Buccal Nasal Description
More informationThe reality of LOH-symptoms
The reality of LOH-symptoms PRISM IV Bruges, Belgium September 25-26, 2014 Dr. Herman Leliefeld Androsmannenkliniek The Netherlands The reality of LOH symptoms male external & internal genitalia Testosterone
More informationTestosterone Replacement in Adults. John A. Seibel, MD, FACP, MACE
Testosterone Replacement in Adults John A. Seibel, MD, FACP, MACE Disclosures None! *Privately Authenticated Definition of Male Hypogonadism inadequate gonadal function, as manifested by deficiencies in
More informationDiagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes
Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes Adrian Dobs, M.D., M.H.S. Professor of Medicine and Oncology The Johns Hopkins University School of Medicine
More informationUpdate In Hyperthyroidism
Update In Hyperthyroidism CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright
More informationRecommendations on the diagnosis, treatment and monitoring of Testosterone deficiency (TD) in adult men
Recommendations on the diagnosis, treatment and monitoring of Testosterone deficiency (TD) in adult men Bruno Lunenfeld, George Mskhalaya, Svetlana Kalinchenko, Yulia Tishova, Michael Zitzmann, Stefan
More informationin Primary Care (Part 2) Jonathan R. Anolik, MD, FACP, FACE Lewis Katz School of Medicine at Temple University
Common Endocrine Problems Seen in Primary Care (Part 2) Lecture #34 Jonathan R. Anolik, MD, FACP, FACE Lewis Katz School of Medicine at Temple University None Conflict of Interest Topics to be Covered
More informationTestosterone: Current Opinion and Controversy
Testosterone: Current Opinion and Controversy Ravi Kacker, MD Metrowest Urology (508) 655 4422 Medical Office Building at Leonard Morse Hospital Disclosures MHB Labs President and CEO of Drug Development
More informationTUE Physician Guidelines Medical Information to Support the Decisions of TUE Committees MALE HYPOGONADISM MALE HYPOGONADISM
1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of testosterone (testosterone deficiency) and in some instances normal
More informationOVERVIEW OF PRESENTATION
Thanh D. Hoang, DO, FACP, FACE Division of Endocrinology Department of Internal Medicine WRNMMC 13 Aug 2018 OVERVIEW OF PRESENTATION Take Home Points Definition of Hypogonadism Clinical Manifestations
More informationBasics of Male Libido: Dysfunction & Treatment. Ripu Hundal MD FACE First State Endocrinology Newark, DE
Basics of Male Libido: Dysfunction & Treatment Ripu Hundal MD FACE First State Endocrinology Newark, DE Sexual Hormones Steroid hormones Commonly referred to as male sex hormones and female sex hormones,
More informationTestim 1 Gel: Review of Clinical Data
European Urology Supplements European Urology Supplements 4 (2005) 24 30 Testim 1 Gel: Review of Clinical Data Tom A. McNicholas* Department of Urology, Lister Hospital, Corey s Mill Lane, Stevenage, Hertfordshire
More informationHORMONE THERAPY IN AGING MALE ATHLETES
DISCLOSURES HORMONE THERAPY IN AGING MALE ATHLETES No relevant affiliations or financial interests When, Why and is it Safe? OBJECTIVES Summarize the benefits of optimizing hormone balance Examine the
More informationImplantable Hormone Pellets
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationTestosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline
SPECIAL FEATURE Clinical Practice Guideline Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline Shalender Bhasin, Glenn R. Cunningham, Frances
More informationTestosterone and the Prostate
Testosterone and the Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David and Vicki M. Crawford Endowed Chair in Urologic Oncology University
More informationMale New Patient Package
Male New Patient Package The contents of this package are your first step to restore your vitality. Please take time to read this carefully and answer all the questions as completely as possible. Thank
More informationHIGHLIGHTS. From Testosterone Update Disease State Theater. American Urological Association and Endocrine Society Annual Meetings
HIGHLIGHTS From Testosterone Update Disease State Theater Presentations held at the 2008 American Urological Association and Endocrine Society Annual Meetings Jointly sponsored by the Annenberg Center
More informationHormone Replacement Therapy For Men Consultation Information
Hormone Replacement Therapy For Men Consultation Information www.urologyaustin.com Biological Aging and Hormones As we age, a natural degeneration and aging of organs causes the levels of our hormones
More informationDoes TRT Induce Prostate Cancer?
Does TRT Induce Prostate Cancer? Prism VI, Bruges, Belgium 21-22November 2014 Herman Leliefeld, Urologist, Utrecht The Netherlands Does TRT Induce Prostate Cancer? Why is it a controversial topic? Is there
More informationTESTOSTERONE DEFINITION
DEFINITION A hormone that is a hydroxyl steroid ketone (C19H28O2) produced especially by the testes or made synthetically and that is responsible for inducing and maintaining male secondary sex characteristics.
More informationGP guide to testosterone replacement therapy in men
GP guide to testosterone replacement therapy in men SPL Mike Kirby FRCP Professor Mike Kirby describes how the diagnosis and treatment of test - osterone deficiency in primary care can lead to improved
More informationConsent for Testosterone Therapy-Men Revised 4/10/18
Consent for Testosterone Therapy in Men You have been diagnosed with or have an increased risk of having a hormone deficiency and your provider has recommended treatment with bio-identical hormone replacement
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Testosterone Therapy Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 7 References... 7 Effective Date... 1/1/2018
More informationHormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase
Patient Name: Patient DOB: Gender: Physician: Test Hormone Balance - Female Report SAMPLE Grote, Mary Jane Batch Number: B6437 2/16/1954 Accession Number: N52281 F Date Received: 2/3/2015 Any Lab Test
More informationA USER S GUIDE WHAT EVERY MAN NEEDS TO KNOW
A USER S GUIDE WHAT EVERY MAN NEEDS TO KNOW 1. Why men need to know more Good health is vital for a happy and full life. But, with work and family responsibilities, men often overlook their own health
More informationPatient education for transgender feminizing hormone therapy
Date name DOB Patient education for transgender feminizing hormone therapy o Some transsexual, transgender, and gender non-conforming people choose to take hormone therapy to treat gender dysphoria and
More informationMale Patient Questionnaire & History
Male Patient Questionnaire & History Name: Today s Date: (Last) (First) (Middle) Date of Birth: Age: Weight: Occupation: Home Address: City: State: Zip: E-Mail Address: May we contact you via E-Mail? (
More informationR. Charles Welliver, Jr.,* Herbert J. Wiser, Robert E. Brannigan, Kendall Feia, Manoj Monga and Tobias S. K ohler
Sexual Function/Infertility Validity of Midday Total Testosterone Levels in Older Men with Erectile Dysfunction R. Charles Welliver, Jr.,* Herbert J. Wiser, Robert E. Brannigan, Kendall Feia, Manoj Monga
More informationTestosterone Deficiency Syndrome. Time for Proper Personalised Care
Prof Geoffrey Hackett Good Hope Hospital Sutton Coldfield Testosterone Deficiency Syndrome Time for Proper Personalised Care BSSM Testosterone Guidelines 2017 www.bssm.org.uk Recommendations Diagnosis
More informationTRT and localized protate cancer
TRT and localized protate cancer Frans M. J. Debruyne Professor of Urology PRISM BRUGES Increased risk of prostate cancer with TRT? Prostate cancer Testosterone and Prostate Cancer There appears to be
More informationOptions for Treatment of Hypogonadism in Men Desiring Fertility Preservation
Options for Treatment of Hypogonadism in Men Desiring Fertility Preservation Natan Bar-Chama MD Director Male Reproductive Medicine and Surgery The Mount Sinai School of Medicine New York NY American Association
More informationIs T for Me? Testosterone Replacement Therapy in Older Males
Is T for Me? Testosterone Replacement Therapy in Older Males Natalia Malesa, PharmD, MSIS PGY1 Community Pharmacy Resident H-E-B Pharmacy The University of Texas at Austin Objectives At the end of this
More information